Merck Retains Interest in Select AstraZeneca APIs
Merck & Co. advised AstraZeneca (London) that it will not exercise its option to sell its interest in certain AstraZeneca non-proton pump inhibitor (non-PPI) products this year.
Whitehouse Station, NJ (Feb.28)-Merck & Co. advised AstraZeneca (London) that it will not exercise its option to sell its interest in certain AstraZeneca non-proton pump inhibitor (non-PPI) products this year. Those products are “Atacand” (candesartan cilexetil), “Lexxel” (enalapril maleate and felodipine), “Plendil” (felodipine), and “Entocort” (budesonide).
As a result of this decision, AstraZeneca will have an option to acquire Merck's interest in these non-PPI products in the first half of 2010. If AstraZeneca exercises that option, AstraZeneca will have another option to acquire Merck's interest in the PPI products, including Nexium (esomeprazole) in 2012. Merck will still receive certain payments from AstraZeneca in the first quarter of 2008 in the net amount of $2.6 billion, which represents a payment of approximately $4.0 billion offset by a loan repayment of $1.4 billion to AstraZeneca from Merck.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
